Coherus BioSciences Inc
CHRS0.880USD
+0.002+0.27%
Market hours （ET）Quotes delayed by 15 min
102.02MMarket Cap
LossP/E TTM
More Details of Coherus BioSciences Inc Company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
Company Info
Ticker SymbolCHRS
Company nameCoherus Oncology Inc
IPO dateNov 06, 2014
CEOMr. Dennis M. (Denny) Lanfear
Number of employees228
Security typeOrdinary Share
Fiscal year-endNov 06
Address333 Twin Dolphin Dr, Suite 600
CityREDWOOD CITY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94065
Phone16506493530
Websitehttps://www.coherus.com/
Ticker SymbolCHRS
IPO dateNov 06, 2014
CEOMr. Dennis M. (Denny) Lanfear
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Dennis M. (Denny) Lanfear
Mr. Dennis M. (Denny) Lanfear
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.20M
--
Ms. Jami Taylor
Ms. Jami Taylor
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Charles W. Newton
Mr. Charles W. Newton
Independent Director
Independent Director
--
--
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
--
--
Mr. Mats L. Wahlstrom
Mr. Mats L. Wahlstrom
Lead Independent Director
Lead Independent Director
--
--
Ms. Rita A. Karachun
Ms. Rita A. Karachun
Independent Director
Independent Director
--
--
Mr. Bryan Mcmichael
Mr. Bryan Mcmichael
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Georgia L. Erbez
Ms. Georgia L. Erbez
Independent Director
Independent Director
--
--
Dr. Michael Ryan, Pharm.D.
Dr. Michael Ryan, Pharm.D.
Independent Director
Independent Director
--
--
Dr. Theresa M. Lavallee, Ph.D.
Dr. Theresa M. Lavallee, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Dennis M. (Denny) Lanfear
Mr. Dennis M. (Denny) Lanfear
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.20M
--
Ms. Jami Taylor
Ms. Jami Taylor
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Charles W. Newton
Mr. Charles W. Newton
Independent Director
Independent Director
--
--
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
--
--
Mr. Mats L. Wahlstrom
Mr. Mats L. Wahlstrom
Lead Independent Director
Lead Independent Director
--
--
Ms. Rita A. Karachun
Ms. Rita A. Karachun
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
LOQTORZI
7.35M
96.70%
Other
251.00K
3.30%
By RegionUSD
Name
Revenue
Proportion
United States
7.60M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
LOQTORZI
7.35M
96.70%
Other
251.00K
3.30%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.62%
BlackRock Institutional Trust Company, N.A.
7.36%
Satterfield (Thomas A Jr)
5.18%
Rubric Capital Management LP
4.54%
Tang Capital Management, LLC
4.40%
Other
68.91%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.62%
BlackRock Institutional Trust Company, N.A.
7.36%
Satterfield (Thomas A Jr)
5.18%
Rubric Capital Management LP
4.54%
Tang Capital Management, LLC
4.40%
Other
68.91%
Shareholder Types
Shareholders
Proportion
Investment Advisor
25.80%
Hedge Fund
12.63%
Investment Advisor/Hedge Fund
10.07%
Individual Investor
6.54%
Private Equity
2.62%
Research Firm
2.00%
Pension Fund
0.34%
Bank and Trust
0.19%
Family Office
0.07%
Other
39.75%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
389
70.40M
60.73%
-31.53M
2025Q1
406
64.71M
55.82%
-38.24M
2024Q4
416
68.70M
59.63%
-38.92M
2024Q3
421
81.72M
70.94%
-25.68M
2024Q2
424
87.07M
75.90%
-23.84M
2024Q1
438
87.85M
77.46%
-18.52M
2023Q4
449
89.54M
79.86%
-21.13M
2023Q3
447
100.50M
94.80%
-3.53M
2023Q2
432
93.48M
99.16%
-5.82M
2023Q1
445
84.77M
105.41%
-12.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
11.15M
9.62%
-2.47K
-0.02%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.53M
7.36%
-128.99K
-1.49%
Mar 31, 2025
Satterfield (Thomas A Jr)
6.01M
5.18%
+6.01M
--
Apr 14, 2025
Rubric Capital Management LP
5.26M
4.54%
--
--
Mar 31, 2025
Tang Capital Management, LLC
5.10M
4.4%
+1.45M
+39.65%
Mar 31, 2025
Kohlberg Kravis Roberts & Co. L.P.
3.04M
2.62%
+500.00
+0.02%
Apr 24, 2025
Millennium Management LLC
2.90M
2.5%
+1.85M
+176.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.66M
2.29%
+55.86K
+2.15%
Mar 31, 2025
State Street Global Advisors (US)
2.23M
1.92%
+49.82K
+2.29%
Mar 31, 2025
CM Management, LLC
2.15M
1.85%
+97.50K
+4.76%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
WisdomTree US SmallCap Fund
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
Strategas Global Policy Opportunities ETF
0%
JPMorgan BetaBuilders US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
WisdomTree US SmallCap Fund
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Strategas Global Policy Opportunities ETF
Proportion0%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
